{
    "organizations": [],
    "uuid": "e14aa0004b44ad7e7e05b561a5ef8543b72337bc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-viveve-announces-initiation-of-viv/brief-viveve-announces-initiation-of-viveve-ii-clinical-study-idUSFWN1SN0NZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Viveve Announces Initiation Of Viveve II Clinical Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Viveve Medical Inc:\n* VIVEVE ANNOUNCES INITIATION OF VIVEVE II CLINICAL STUDY * VIVEVE MEDICAL INC - ANTICIPATE SUBMITTING 30-DAY SAFETY DATA FROM FIRST 25 TREATED PATIENTS FOR VIVEVE II STUDY TO FDA FOR REVIEW BY END OF Q2 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-16T20:36:00.000+03:00",
    "crawled": "2018-05-17T14:38:51.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "viveve",
        "medical",
        "inc",
        "viveve",
        "announces",
        "initiation",
        "viveve",
        "ii",
        "clinical",
        "study",
        "viveve",
        "medical",
        "inc",
        "anticipate",
        "submitting",
        "safety",
        "data",
        "first",
        "treated",
        "patient",
        "viveve",
        "ii",
        "study",
        "fda",
        "review",
        "end",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}